Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Aug 20;5(2):e1073882. doi: 10.1080/2162402X.2015.1073882

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

PMC Copyright notice

Figure 6. — TEM lymphangiogenic activity is supported by cross-talk between VEGFR and TIE-2 pathways. (A) In vivo corneal vascularization assay was used to assess the lymphangiogenic activity of TEM isolated from human breast tumors. Lymphatic vessels emerging from the peripheral limbal vasculature were labeled with LYVE-1-specific antibodies in sagittal sections of mouse eyes. Double-headed and single arrows depict cornea and iris respectively. Scale bar: 100 μm; (B) Confocal microscopy images of TEM sorted from dissociated breast tumor showing expression of VEGF-A, -C and -D. Scale bar: 5μm; (C) TEM isolated from dissociated breast tumors were exposed to TIE-2- and VEGFR-specific kinase inhibitors and their hem- and lymphangiogenic activities were measured in vitro using a sprouting assay of HUVEC and LEC respectively (t test, *** p <0.001, **** p < 0.0001).